A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $12 to $30

Moomoo NewsDec 17 08:00 ET · Ratings

Annexon Biosciences' ANX005: Strong Buy Rating Backed by Promising Efficacy and Sales Potential

TipRanksDec 16 14:25 ET · Ratings

Annexon, Inc. Reports Positive Real-World Evidence Study Results Supporting ANX005 for Guillain-Barré Syndrome Treatment

Quiver QuantitativeDec 16 07:41 ET

Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome

BenzingaDec 16 07:33 ET

Express News | Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)

ReutersDec 16 07:30 ET

Annexon Insider Buyers Pleased With US$571k Return On Investment

Simply Wall StDec 13 05:06 ET